Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - Implications for anti-PcrV immunotherapy

Microbial Pathogenesis

Volumn 48, Issue 6, 2010, Pages 197-204

  Lynch, Susan V ^a   Flanagan, Judith L ^a   Sawa, Teiji ^a   Fang, Alice ^a   Baek, Marshall S ^a   Rubio Mills, Amua ^a   Ajayi, Temitayo ^a   Yanagihara, Katsunori ^c   Hirakata, Yoichi ^c   Kohno, Shigeru ^c   Misset, Benoit ^d   Nguyen, Jean Claude ^d   Wiener Kronish, Jeanine P ^a,b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAINT JOSEPH HOSPITAL   (France)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti PcrV IgG; Cytotoxicity; Pseudomonas aeruginosa; Single nucleotide polymorphism; Type III secretion

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN PCRV; PROTEIN PCRV IMMUNOGLOBULIN G ANTIBODY; PSEUDOMONAS AERUGINOSA TYPE III SECRETION PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG TARGETING; FRANCE; GENE EXPRESSION; GENE SEQUENCE; GENETIC CONSERVATION; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; IMMUNOTHERAPY; JAPAN; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CELL LINE; DNA, BACTERIAL; FRANCE; HUMANS; IMMUNOGLOBULIN G; JAPAN; MUTATION; POLYMORPHISM, GENETIC; PORE FORMING CYTOTOXIC PROTEINS; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; SEQUENCE ANALYSIS, DNA; UNITED STATES;

MURINAE; PSEUDOMONAS AERUGINOSA;

EID: 77952243280     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2010.02.008     Document Type: Article

References (30)

1. Allmond L.R., Ajayi T., Moriyama K., Wiener-Kronish J.P., Sawa T. V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa. J Clin Microbiol 2004, 42:3857-3860.
2. Almirall J., Mesalles E., Klamburg J., Parra O., Agudo A. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995, 107:511-516.
3. Burrows T.W. An antigen determining virulence in Pasteurella pestis. Nature 1956, 177:426-427.
4. Burrows T.W., Bacon G.A. The basis of virulence in Pasteurella pestis: an antigen determining virulence. Br J Exp Pathol 1956, 37:481-493.
5. Craven D.E., Steger K.A. Nosocomial pneumonia in mechanically ventilated adult patients: epidemology and prevention in 1996. Semin Respir Infect 1996, 11:32-53.
6. Crouch Brewer S., Wunderink R.G., Jones C.B., Leeper K.V. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996, 109:1019-1029.
7. DeBord K.L., Lee V.T., Schneewind O. Roles of LcrG and LcrV during type III targeting of effector Yops by Yersinia enterocolitica. J Bacteriol 2001, 183:4588-4598.
8. Duncan C.J., Scott S. What acused the black deadth?. Postgrad Med J 2005, 81:315-320.
9. Elvin S.J., Eyles J.E., Howard K.A., Ravichandran E., Somavarappu S., Alpar H.O., et al. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine 2005, 15:4433-4439.
10. Faure K., Fujimoto J., Shimabukuro D.W., Ajayi T., Shime N., Moriyama K., et al. Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model. J Immune Ther Vaccines 2003, 1:2.
11. Frank D.W., Vallis A., Wiener-Kronish J.P., Roy-Burman A., Spack E.G., Mullaney B.P., et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002, 186:64-73.
12. Hill J., Leary S.E., Griffin K.F., Williamson E.D., Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 1997, 65:4476-4482.
13. Holder I.A. Pseudomonas immunotherapy: a historical overview. Vaccine 2004, 22:831-839.
14. Holder I.A., Neely A.N., Frank D.W. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect Immun 2001, 69:5908-5910.
15. Hueck C.J. Type III protein secretion systems in bacterial pathogens of plants and animals. Microbiol Mol Biol Rev 1998, 62:379-433.
16. Kurahashi K., Kajikawa O., Sawa T., Ohara M., Gropper M.A., Frank D.W., et al. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999, 104:743-750.
17. Matson J.S., Nilles M.L. LcrG-LcrV interaction is required for control of Yops secretion in Yersinia pestis. J. Bacteriol. 2001, 183(17):5082-5091.
18. Nanao M., Ricard-Blum S., Di Guilmi A.M., Lemaire D., Lascoux D., Chabert J., et al. Type III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactions. BMC Microbiol 2003, 3:21.
19. Neely A.N., Holder I.A., Wiener-Kronish J.P., Sawa T. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 2005, 31:153-158.
20. Nicas T.I., Iglewski B.H. Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S. Infect Immun 1984, 45:470-474.
21. Roggenkamp A., Geiger A.M., Leitritz L., Kessler A., Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 1997, 65:446-451.
22. Roy-Burman A., Savel R.H., Racine S., Swanson B.L., Revadigar N.S., Fujimoto J., et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001, 183:1767-1774.
23. Rumbaugh K.P., Sawa T., Wiener-Kronish J.P. New perspectives on prevention and management of Pseudomonas aeruginosa infections. In Severe infections caused by Pseudomonas aeruginosa 2003, Kluwer Academic Publishers, Boston. A.R. Hauser (Ed.).
24. Sato H., Feix J.B., Hillard C.J., Frank D.W. Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU. J Bacteriol 2005, 187:1192-1195.
25. Sato H., Frank D.W. ExoU is a potent intracellular phospholipase. Mol Microbiol 2004, 53:1279-1290.
26. Sawa T., Wiener-Kronish J.P. A therapeutic strategy against the shared virulence mechanism utilized by both Yersinia pestis and Pseudomonas aeruginosa. Anesthesiol Clin North Am 2004, 22:591-606.
27. Sawa T., Yahr T.L., Ohara M., Kurahashi K., Gropper M.A., Wiener-Kronish J.P., et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999, 5:392-398.
28. Schmidt A., Schaffelhofer S., Muller K., Rollinghoff M., Beuscher H.U. Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity. Microb Pathog 1999, 26:221-233.
29. Shime N., Sawa T., Fujimoto J., Faure K., Allmond L.R., Karaca T., et al. Therapeutic administration of anti-PcrV F(ab′)(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 2001, 167:5880-5886.
30. Une T., Brubaker R.R. Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol 1984, 133:2226-2230.